(Q81290162)
Statements
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders (English)
Lucio N Gordan
William B Grow
Annette Pusateri
Vonda Douglas
Nancy P Mendenhall
18 January 2005